Dr Sandra Guillen
Department: Clinical Science and Services
Campus: Hawkshead
Clinical Groups: Small Animal Oncology
Mober H, Gramer I, Schofield I, Blackwood L, Killick D, Priestnall SL, Guillén A (2022) Clinical presentation, treatment and outcome of canine malignant mesothelioma: 34 cases. Vet Comp Oncol, 20(1):304-312
Guillén A, Smallwood K, Killick D (2021) Molecular pathology in the cancer clinic- where are we now and where are we headed? J Small Anim Pract?, 62(7):507-520
Guillén A, Stiborova K, Ressel L, Blackwood L, Finotello R, Amores-Fuster I, Jama N, Killick D (2021) Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma. Res Vet Sci, 137:226-234
Smith VA, Knottenbelt C, Watson DG, Mellor DJ, Guillén A, Philp HS, Keegan S, Marrington M, Genassi C, Cave T, McBrearty AR. (2020) Hair nicotine concentration of cats with gastrointestinal lymphoma and unaffected control cases. The Veterinary Record, 186(13):414
Guillén A, Rossanese M, Ricci E, German A.J, Blackwood L. (2020) Gastric intravascular lymphoma: case report and literature review. Journal of the American Animal Hospitalization Association, 56(3):185
Guillén A, Finotello R, Killick D, Harper A, Wynne P, Blackwood L. (2019) Toxicity of cytarabine constant rate infusion in dogs with high grade non-Hodgkin lymphoma with bone marrow or central nervous system involvement. Australian Veterinary Journal, 98(3):69-78
Guillén A, Ressel L, Finotello R, German A.J, Blackwood L. Non-islet cell tumour hypoglycaemia in a cat with hepatocellular carcinoma (2019) Journal of Feline Medicine and Surgery Open Case Reports, 26:5.
-
Prospective evaluation of palliative and adjuvant toceranib phosphate therapy in dogs diagnosed with metastatic or recurrent insulinomas
Insulinomas are the most common tumours of the pancreas in dogs. This multi-institutional prospective study evaluates the effectiveness of the drug toceranib phosphate in the treatment of insulinomas in dogs. This is an observational multi-institutional prospective trial. Client preferences regarding control/treatment group allocation will be followed and enrolment will not be blinded or randomised.